Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection

Abstract

To determine whether needle size influences a patient's perception of pain, 50 patients requiring hormonal manipulation for prostate cancer were blindfolded and randomised to receive two goserelin (‘Zoladex’) or two leuprorelin (‘Prostap’) injections, using 16- or 23-gauge needles, respectively. Median visual analogue scale pain scores for the first injections of goserelin and leuprorelin were below the level of clinical significance and were not statistically different. Mean administration time for goserelin was significantly shorter than for leuprorelin. In conclusion, there was no statistically significant difference in pain experienced on injection of goserelin and leuprorelin when patients were unaware of needle size.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Parkin DM, Bray FI, Devesa SS . Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4–S66.

    Article  Google Scholar 

  2. Kaisary AV et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502–508.

    Article  CAS  Google Scholar 

  3. Vogelzang NJ et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995; 46: 220–226.

    Article  CAS  Google Scholar 

  4. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281–1286.

  5. Prayer-Galetti T et al. Disease free survival in patients with pathological ‘C STAGE’ prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment. Eur Urol 2000; 38: 504 (abstract 48).

    Google Scholar 

  6. Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–108.

    Article  CAS  Google Scholar 

  7. Pilepich MV et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Soc Clin Oncol 2003; 22: 381 (abstract 1530).

    Google Scholar 

  8. Messing E et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003; 169: 396 (abstract 1480).

    Google Scholar 

  9. Hanks GE et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972–3978.

    Article  CAS  Google Scholar 

  10. Bono AV et al. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. Urology 2001; 57: 117–121.

    Article  CAS  Google Scholar 

  11. Schulman CC et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol 2000; 38: 706–713.

    Article  CAS  Google Scholar 

  12. Pilepich MV et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243–1252.

    Article  CAS  Google Scholar 

  13. Prescribing information for ‘Zoladex’. 2003.

  14. Prescribing information for ‘Prostap’. 2003.

  15. Williams G, Lindsay S, Bowsher WG . Randomised crossover trial to assess the tolerability of LHRH analogue administration. Prostate Cancer Prost Dis 2003; 6: 187–189.

    Article  CAS  Google Scholar 

  16. Powell CV, Kelly AM, Williams A . Determining the minimum clinically significant difference in visual analog pain score for children. Ann Emerg Med 2001; 37: 28–31.

    Article  CAS  Google Scholar 

  17. Cooley C, Morgan G . Preparation and administration of goserelin (‘Zoladex’) and leuprorelin: a comparative assessment of clinical convenience and nurse perceptions. Oral presentation at the BAUN Annual Conference and Exhibition 2003, Telford, UK, 4–6 November, 2003.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B S I Montgomery.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montgomery, B., Borwell, J. & Higgins, D. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection. Prostate Cancer Prostatic Dis 8, 66–68 (2005). https://doi.org/10.1038/sj.pcan.4500778

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500778

Keywords

This article is cited by

Search

Quick links